| Dr Caroline A Schepker, DO | |
|
7 Marsh Brook Dr Ste 200, Somersworth, NH 03878-6529 | |
| (603) 742-4222 | |
| (603) 742-4448 |
| Full Name | Dr Caroline A Schepker |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 9 Years |
| Location | 7 Marsh Brook Dr Ste 200, Somersworth, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417310079 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wentworth-douglass Hospital | Dover, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wentworth Douglass Physician Corporation | 5496749848 | 372 |
News Archive
Results were released today from the first two clinical studies designed specifically to examine the effects of the heart drug sacubitril/valsartan on the structure and function of the failing heart.
VTT Technical Research Centre of Finland and A*STAR Agency for Science, Technology and Research from Singapore have developed remote healthcare services that allow patients to be treated globally independent of time and location and irrespective of the solutions provided by hardware and data system suppliers. In Finland, the first trial services for treating cardiac patients and patients suffering from chronic illnesses have been promising.
In a Clinical trial in China, a vaccine has been found to protect against Hepatitis E. Hepatitis E virus, usually spread via contaminated food and faeces usually runs its course before the patient recovers. However it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent. It can also kill 5 to 25 percent of affected pregnant women and those who survive can suffer high rates of miscarriage. Around a third of the world's population have been infected by the virus say researchers.
In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.
› Verified 1 days ago
| Entity Name | Wentworth Douglass Physician Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447352430 PECOS PAC ID: 5496749848 Enrollment ID: O20040409000433 |
News Archive
Results were released today from the first two clinical studies designed specifically to examine the effects of the heart drug sacubitril/valsartan on the structure and function of the failing heart.
VTT Technical Research Centre of Finland and A*STAR Agency for Science, Technology and Research from Singapore have developed remote healthcare services that allow patients to be treated globally independent of time and location and irrespective of the solutions provided by hardware and data system suppliers. In Finland, the first trial services for treating cardiac patients and patients suffering from chronic illnesses have been promising.
In a Clinical trial in China, a vaccine has been found to protect against Hepatitis E. Hepatitis E virus, usually spread via contaminated food and faeces usually runs its course before the patient recovers. However it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent. It can also kill 5 to 25 percent of affected pregnant women and those who survive can suffer high rates of miscarriage. Around a third of the world's population have been infected by the virus say researchers.
In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Caroline A Schepker, DO Po Box 412503, Boston, MA 02241-2503 Ph: () - | Dr Caroline A Schepker, DO 7 Marsh Brook Dr Ste 200, Somersworth, NH 03878-6529 Ph: (603) 742-4222 |
News Archive
Results were released today from the first two clinical studies designed specifically to examine the effects of the heart drug sacubitril/valsartan on the structure and function of the failing heart.
VTT Technical Research Centre of Finland and A*STAR Agency for Science, Technology and Research from Singapore have developed remote healthcare services that allow patients to be treated globally independent of time and location and irrespective of the solutions provided by hardware and data system suppliers. In Finland, the first trial services for treating cardiac patients and patients suffering from chronic illnesses have been promising.
In a Clinical trial in China, a vaccine has been found to protect against Hepatitis E. Hepatitis E virus, usually spread via contaminated food and faeces usually runs its course before the patient recovers. However it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent. It can also kill 5 to 25 percent of affected pregnant women and those who survive can suffer high rates of miscarriage. Around a third of the world's population have been infected by the virus say researchers.
In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.
› Verified 1 days ago
Dr. David John Cormier, DO, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 7 Marsh Brook Dr Ste 100, Somersworth, NH 03878 Phone: 603-742-2007 Fax: 603-749-4605 |